In pre-market trading, shares of Aquestive Therapeutics Inc. (AQST) rose by 9.85% to $3.57 as of last check. In Tuesday’s session, AQST stock lost -1.81% to close at $3.25. The volume of AQST stock was 0.22 million shares, which was lower than its average daily volume of 0.56 million shares over the past 50 days. Over the last week, AQST stock was down -3.85%, a decline of -42.88% over the past 12 months.
Within the past three months, the AQST stock has fallen by 10.96%, while within the past six months, it has dropped by 39.81%. In addition, AQST has a current market capitalization of $126.20 million, with 35.56 million outstanding shares. The AQST stock rose following release of quarterly results.
AQST’s performance: how did it fare?
Pharmaceutical company Aquestive specializes in using innovative technologies to alleviate therapeutic issues and improve medications for patients. Sympazan, an internally developed proprietary product, has been commercialized to date by AQST. As part of AQST’s commercial pipeline, it has proprietary products focused on treating diseases of the central nervous system (CNS), and other unmet needs.
In addition, AQST is developing orally-administered complex molecules to replace invasive therapies currently used. AQST has proven capabilities for drug development and commercialization and collaborates with other pharmaceutical companies to create new molecules and brings them to market with proprietary, best-in-class technologies like PharmFilm.
Aquestive yesterday provided an update on recent developments in its business and financial results for the second quarter ended June 30, 2021.
AQST Stock Quarterly financial highlights:
- Revenue at AQST for the second quarter of 2021 was $15.3 million, compared to $21.7 million for the same period in 2020.
- AQST posted a net loss of $12.4 million for the quarter or $0.33 per share.
- A net loss of $2.3 million, or $0.07 per share, was recorded as of the second quarter of 2020.
- The adjusted EBITDA loss reported by AQST in the second quarter of 2021 was $4.1 million, compared with a gain of $2.9 million in the second quarter of 2020.
- AQST had $34.2 million in cash and cash equivalents at the end of June 2021.
- AQST received net proceeds of $8.6 million from its At-The-Market (ATM) facility during the second quarter of 2021.
An update on the AQST’s activities:
The FDA accepted Libervant’s NDA and gave AQST until December 23rd, 2021, to submit a PDUFA. Aquestive (AQST) is presently pursuing FDA approval for its non-invasive and innovative epilepsy treatment that may benefit the underserved population of patients suffering from refractory epilepsy. Phase-1 recruitment in AQST-109, an oral alternative to injections like EpiPen, is going well and AQST is on schedule to report top-line data in the second half of 2021 as committed.
